■ | Scientific program – 04.12.2025

from 08.00	Door opening Networking Area	Networking Area
08.30-08.45	Opening & Welcome Address of the 57h Annual Meeting of the Swiss Society of Nephrology	Room Theatersaal
08.45-09.30	State of the Art Lecture 1: The UK Kidney Ecosystem - Enabling Clinical Research for adults and children Dr. Louise Oni, Liverpool (UK)	Room Theatersaal
09.30-10.10	Short Oral Session 1 Clinical Nephrology	Room Theatersaal
09.32/SO-04	CENSUS-EU: An observational study to investigate prevalence and burden of chronic kidney disease-associated pruritus in Europe, Switzerland included.	Fabienne Aregger, Bern
09.37/SO-12	Expanding Therapeutic Boundaries: First Experience with Obinutuzumab in a Dialysis Patient with systemic Lupus Erythematodes	Ilirjana Bajraktari, Bern
09.42/SO-08	Diffusion and multiparametric MRI radiomics predict renal function decline in ADPKD	*Matteo Bargagli, Bern
09.47/SO-10	Efficacy and Safety of Palopegteri- paratide Treatment in Adults With Hypoparathyroidism: 3-Year Results From the Phase 3 PaTHway Trial	Jean-Philippe Bertocchio, Paris (FRA)
09.52/SO-27	Regression of proteinuria during pregnancy in women with proteinuric nephropathy: impossible or uncommon?	*Domenico Cozzo, Genève
09.57/SO-20	Nephrologists' Survey on the Management of Chronic Kidney Disease-associated Mineral and Bone Disorders in Switzerland	* Noemi Galliker, Burgdorf
10.02/SO-29	Urinary biomarker analysis reveals rapid intra-renal anti-inflammatory and anti-fibrotic effects of sparsentan in IgA nephropathy (IgAN) in the SPARTAN study	Stéphane Genoud, Villars-sur-Glâne

^{* =} YSN submission

09.30-10.10	Short Oral Session 2 Basic Science	Room Ballsaal
09.32/SO-09	Dysregulation of a Nephrin-Associated Phospho-Protein Network Impairs Filtration and Podocyte Adhesion	* Carolin Eul, Zürich
09.37/SO-02	Biochemical and molecular biological analysis of (likely) pathogenic NPHS2 missense variants	* Carolin Eul, Zürich
09.47/SO-22	Oxygenation at birth restores NKCC2 and NCC expression, partially explaining the transient nature of Bartter Syndrome type 5	Stefan Rudloff, Bern
09.52/SO-06	Could TrkC activation provide a potential avenue for therapeutic intervention in AKI?	Sucheta Sridhar, Zürich
09.57/SO-25	Prediction of NPHS1 Variant Pathoge- nicity in Monogenic Nephrotic Syndrome	Sucheta Sridhar, Zürich
10.02/SO-23	Pegcetacoplan demonstrates sustained 52-week efficacy and safety across subgroups in C3G and primary IC-MPGN: results from the VALIANT trial	Fadi Fakhouri, Lausanne
10.10-10.20	Short break	Networking Area
10.20-11.00	Short Oral Session 3 Clinical Nephrology	Room Theatersaal
10.22/SO-28	The use of SGLT-2 inhibitors in kidney transplant recipients with diabetes: a single-centre experience	Katarina Liskova, Basel
10.27/SO-13	Feasibility of Implementing Electronic Patient-Reported Outcome Measures (ePROMs) in Hemodialysis: A Pilot Study in a Secondary Care Hospital in Switzerland	* Thomas Reich, Solothurn
10.32/SO-07	Diagnostic and therapeutic manage- ment in severe hyponatremia: impact of guideline adherence on clinical outcomes	Michael Reuster, Bern
10.37/SO-17	Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Secondary Prevention of Kidney Stones: a Randomized, Double-blind, Crossover Trial (INDAPACHLOR Trial)	* Martin Scoglio, Bern

^{* =} YSN submission

10.42/SO-18	Late-onset Cobalamin C deficiency associated atypical hemolytic uremic syndrome – diagnostic pitfalls: a case report.	Martha Stampfli, Bern
10.47/SO-21	Oral Glucocorticoid Burden in Lupus Nephritis: A Swiss Cohort Analysis	* Maria Wallner, St. Gallen
10.52/SO-26	Proteomic Profiling Reveals Complement and Endothelin Pathway Activation in Recurrent IgA Nephropathy	Matthieu Halfon, Lausanne
10.57/SO-11	Epidemiological and Genetic Investigation of Pneumocystis jirovecii Pneumonia Outbreak in Kidney Transplant Recipients: Evidence for Human-to-Human Transmission?	* Laura Cereghetti, Lugano
10.20-11.00	Short Oral Session 4 Transplantation	Room Ballsaal
10.22/SO-15	HLA Class II on Urinary EVs: A Marker of Acute Renal Allograft Injury	Jakob E. Brune, Basel
10.27/SO-14	First Swiss experience with Sparsentan in reducing proteinuria in a transplant recipient with recurrent IgA nephropathy - a case report	Rüdiger Eisel, Altstätten
10.32/SO-03	Case report: belatacept-induced colitis in a renal transplant recipient	* Aurélie Huber, Genève
10.37/SO-24	Prediction and outcome of recurrent membranous nephropathy after kidney transplantation – data from the Swiss Transplant Cohort Study	Laila-Yasmin Mani, Bern
10.42/SO-01	aggressive drug deprescribing in selected patients after belatacept conversion	Corinna Pietz, Bern
10.47/SO-16	Impact of Metamizol Exposure on Early Tacrolimus Levels in KT Recipients	* Diana Szücs, Bern
10.52/SO-05	Correlation of Banff-based Activity and Chronicity Indices with Injury Dimen- sion, Rejection Classifier, and Rejection Archetype Scores from Biopsy-based Transcript Diagnostics	* Florian Westphal, Zürich
11.00-11.30	Coffee break	Networking Area

^{* =} YSN submission

11.30-12.15	Parallel Symposium by Boehringer Ingelheim The CKD patient journey: snapshot from Switzerland and innovations from the UK Prof. Smeeta Sinha, Manchester (UK) Prof. Grégoire Wuerzner, Lausanne Chair: Prof. Andrew Hall, Zürich	Room Theatersaal
11.30 – 12.15	Parallel Symposium by CSL Vifor IgAN and the 2025 KDIGO Guidelines: DEARA's Clinical Journey Has Begun PD Dr. Min Jeong Kim, Aarau One Year Later: Learnings from the First DEARA Experience Dr. Domenico Cozzo, Genève Chair: PD Dr. Min Jeong Kim, Aarau	Room Ballsaal
12.15-13.00	State of the Art Lecture 2: The Benefits of Home HD: Pregnancy in Kidney Failure Prof. Dr. Christopher T. Chan, Toronto (CAN)	Room Theatersaal
12.15–13.00	Parallel Symposium by GlaxoSmithKline AG Viral Encounters in Kidney Care: Understanding the Burden of Disease and Role of Vaccination Prof. Dr. med. Uyen Huynh-Do, Bern Prof. Dr. med. Ulrich Heininger, Basel	Room Ballsaal
	Viral Encounters: Understanding the Burden on Kindey Health	Uyen Huynh-Do
	Vaccination Recommendations for Patients with Chronic Renal Disease	Ulrich Heininger
13.00-13.45	Lunch break	Networking Area
13.45-14.30	State of the Art Lecture 3: Advances in therapy for Nephrotic syndrome Prof. Dr. Moin Saleem, Bristol (UK)	Room Theatersaal
13.45–14.30	Parallel Symposium by Ascendis Pharma Replacing What's Missing: Decoding Renal Clues in Hypoparathyroidism Prof. Andrea Trombetti, Genève Dr. Jean-Philippe Bertocchio, Paris (FRA) Chair: Prof. Olivier Bonny, Fribourg	Room Ballsaal

14.30–15.15	Parallel Symposium by Sanofi Nephrological perspectives on thrombotic microangiopathies: When every minute determines organ function Prof. Dr. med. Fadi Fakhouri, Lausanne Prof. Dr. med. Andreas Holbro, Basel	Room Theatersaal
	Decoding the TMA puzzle: Differntial diagnostic challenges through the renal lens	Fadi Fakhouri
	aTTP treatment landscape: Current strategies, best practices and future perspectives	Andreas Holbro
14.30–15.15	Parallel Symposium by AstraZeneca TREAT-CKD - New horizons in improving patient outcomes in complex challenges with CKD Prof. Dr. Grégoire Wuerzner, Lausanne Prof. Dr. Britta George, Zürich Prof. Dr. Sophie de Seigneux, Genève	Room Ballsaal
15.15-15.45	Coffee break	Networking Area
15.45-17.40	Long Oral Session 1+2	Room Theatersaal
	Renal replacement therapy Clinical Nephrology	noon meatersaal
15.48/LO-18	Renal replacement therapy	Paulo de Sousa, Genève
15.48/LO-18 15.59/LO-14	Renal replacement therapy Clinical Nephrology Association of Chronic Fatigue with Dialysis Recovery Time in Hemodialy-	
	Renal replacement therapy Clinical Nephrology Association of Chronic Fatigue with Dialysis Recovery Time in Hemodialysis Patients Practice patterns of routine blood sampling in Swiss hemodialysis centers and their influence on	Paulo de Sousa, Genève
15.59/LO-14	Renal replacement therapy Clinical Nephrology Association of Chronic Fatigue with Dialysis Recovery Time in Hemodialysis Patients Practice patterns of routine blood sampling in Swiss hemodialysis centers and their influence on laboratory data and patient outcome Incremental Dialysis in Switzerland: Trends, patient characteristics,	Paulo de Sousa, Genève * Sophie Feuchter, Frauenfeld

^{* =} YSN submission

16.43/LO-15	Predictors of Stone Recurrence in the NOSTONE Trial: Post Hoc Analysis	* Matteo Bargagli, Bern
16.54/LO-05	Chasing ghosts? - Osmotic Demyelination Syndrome in a high risk cohort of 110 patients with very profound hyponatremia (Serum-Na < 110 mmol/l)	Florian Buchkremer, Luzern
17.05/LO-13	Pegcetacoplan maintains proteinuria reduction and stable eGFR in pediatric patients over 52 weeks in the phase 3 VALIANT trial	Wesley Hayes, Zürich
17.16/LO-17	The Swiss Kidney Biopsy Registry: Results of the Pilot Phase	Andreas Kistler, Frauenfeld
17.27/LO-02	Atypical haemolytic uremic syndrome patients' perspective in the era of complement inhibitors.	Nora Schwotzer, Lausanne
15.45-17.20	Long Oral Session 3+4 Transplantation Basic Science	Room Ballsaal
15.47/LO-10	Immune Pathway Overlap in Recurrent IgA Nephropathy and T cell mediated rejection: A Proteomic Study	Mathieu Halfon, Lausanne
15.57/LO-12	Long-term health risks in living kidney donors: 30 years of prospective experience from the Swiss Organ Living-Donor Health Registry	Patricia Hirt-Minkowski, Basel
16.07/LO-04	Characteristics and outcome of membranous nephropathy in Switzerland – data from the Swiss Transplant Cohort Study	Laila-Yasmin Mani, Bern
16.17/LO-08	Factors affecting allosensitization before kidney retransplantation	* Elena Rho, Zürich
16.27/LO-01	Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplan- tation: The Role of Biopsy-Based Transcript Diagnostics in Differentiating Immune Accommodation from Alloimmune Injury	* Lukas Weidmann, Zürich
16.37/LO-06	Deleterious effect of dietary potassium on kidney fibrosis in the UUO model and the POD ATTAC glomerular disease model	* Thibaut Charlemagne, Genève
16.47/LO-03	Calcium phosphate mineral formation and dynamics in bilateral isch- emia-reperfusion injury	Miguel Correia, Bern

^{* =} YSN submission

16.57/LO-19	Transcriptional mapping of thrombotic microangiopathy in human kidney	Anna Rinaldi, Basel
17.07/LO-16	Sex-specific changes in tubular repair and immune responses after renal ischemia-reperfusion injury.	* Louis Stavart, Lausanne
17.40-18.20	Young Swiss Nephrology Award	Room Theatersaal
17.43 YSN-04	Unravelling the critical role of Wdr72 for kidney function	* Hannah Auwerx, Zürich
17.52 YSN-03	The role of casts in proximal tubule injury and atrophy	* Anna Faivre, Genève
18.01 YSN-01	Inter-Center Variability Of Biopsy-Based Transcript Diagnostics – Comparison Of Banff Lesions With Molecular Scores	* Dusan Harmacek, Zürich
18.10 YSN-02	Short-term effects of an SGLT2 inhibitor on divalent ions in autosomal dominant polycystic kidney disease (ADPKD): the SIDIA trial	* Lorena Roth, Chur
starting at 18.20	Aperitif	Foyer Congress Kursaal Interlaken
starting at 19.30	Networking Dinner and Awards Ceremony	Room Ballsaal

^{* =} YSN submission